ProCE Banner Activity

AUGMENT-101: Phase II Study of Revumenib for R/R KMT2Ar Acute Leukemia

Conference Coverage

Interim analysis from the pivotal phase II AUGMENT-101 trial reported that revumenib monotherapy was associated with a 23% CR/CRh rate and 63% ORR in pediatric and adult patients with R/R KMT2Ar acute leukemia.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.